Sign Out
The efficacy of anidulafungin in neutropenic patients with candidemia and in patients with deep tissue Candida infections or intra-abdominal abscess, and peritonitis has not been established. Patients with increased hepatic enzymes during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy. Patients with rare hereditary problems of fructose intolerance should not take Ecalta.
Use in pregnancy & lactation: Anidulafungin is not recommended in pregnancy.
It is not known whether anidulafungin is excreted in human breast milk.
Use in children: Ecalta is not recommended for use in children <18 years due to insufficient data on safety and efficacy.
